Glenn S Van Aller

Glenn S Van Aller

Central US Merck & Co., Inc. - Kenilworth / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4376421
-
person_outline Glenn S Van Aller's MOST POPULAR ARTICLES
1-) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsMT McCabe, HM Ott, G Ganji, S Korenchuk, C Thompson, GS Van Aller, ...Nature 492 (7427), 108-112, 201216952012
2-) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformationW Béguelin, R Popovic, M Teater, Y Jiang, KL Bunting, M Rosen, H Shen, ...Cancer cell 23 (5), 677-692, 20137842013
3-) A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLCHP Mohammad, KN Smitheman, CD Kamat, D Soong, KE Federowicz, ...Cancer cell 28 (1), 57-69, 20154142015
4-) SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancerPK Mazur, N Reynoird, P Khatri, PWTC Jansen, AW Wilkinson, S Liu, ...Nature 510 (7504), 283-287, 20144132014
5-) Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycinSD Knight, ND Adams, JL Burgess, AM Chaudhari, MG Darcy, ...ACS Medicinal Chemistry Letters 1 (1), 39-43, 20104132010